Portal de Periódicos da CAPES

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies

2021; Cold Spring Harbor Laboratory; Linguagem: Inglês

10.1101/2021.01.19.21249840

Dami A. Collier, Anna De Marco, Isabella A. T. M. Ferreira, Bo Meng, Rawlings Datir, Alexandra C. Walls, Steven A. Kemp, Jessica Bassi, Dora Pinto, Chiara Silacci Fregni, Siro Bianchi, M. Alejandra Tortorici, John E. Bowen, Katja Culap, Stefano Jaconi, Elisabetta Cameroni, Gyorgy Snell, Matteo Samuele Pizzuto, Alessandra Franzetti-Pellanda, Christian Garzoni, Agostino Riva, Anne Elmer, Nathalie Kingston, Barbara Graves, Laura E. McCoy, Kenneth G. C. Smith, John R. Bradley, Nigel Temperton, Lourdes Ceron-Gutierrez L, Gabriela Barcenas‐Morales, William T. Harvey, Herbert W. Virgin, Antonio Lanzavecchia, Luca Piccoli, Rainer Döffinger, Mark R. Wills, David Veesler, Davide Corti, Ravindra K. Gupta,

Viral gastroenteritis research and epidemiology

Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant. This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralisation was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 out of 31), but not in neutralising mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background to reflect newly emerging viruses in the UK led to a more substantial loss of neutralising activity by vaccine-elicited antibodies and mAbs (19 out of 31) over that conferred by the B.1.1.7 mutations alone. E484K emergence on a B.1.1.7 background represents a threat to the vaccine BNT162b.